Testing amivantamab plus FOLFIRI for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with advanced colorectal cancer that has gotten worse after treatment with anti-EGFR therapy. It tests a combination of amivantamab (a targeted drug) and FOLFIRI (a chemotherapy regimen) as a second-line treatment to see if it can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years of age or older.
- You have advanced or metastatic colorectal cancer that cannot be removed by surgery.
- Your tumor does not have mutations in KRAS, NRAS, or BRAF genes, and does not have HER2 amplification (these are tested by your doctor).
- You have already received anti-EGFR therapy and an oxaliplatin-based chemotherapy for your metastatic cancer, and you have not had more than one prior line of treatment.
- You are able to receive FOLFIRI chemotherapy as determined by your doctor.
- You are in generally good health (ECOG performance status 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
Hear when a new RAS/BRAF Wild-type Advanced Colorectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.